TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CStone Pharmaceuticals ( (HK:2616) ) has shared an announcement.
CStone Pharmaceuticals announced the first disclosure of preliminary Phase I data for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, at the 2025 ESMO Annual Congress. The study, conducted in Australia and China, evaluates the safety and antitumor activity of CS2009 in patients with advanced solid tumors, showing favorable safety and tolerability with no dose-limiting toxicity reported. This development marks a significant step in CStone’s efforts to innovate cancer treatment, potentially enhancing its industry positioning and offering new hope for stakeholders involved.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing innovative immuno-oncology therapies. The company is committed to advancing cancer treatment through its pipeline of targeted therapies and antibody-drug conjugates.
Average Trading Volume: 22,683,701
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.01B
For detailed information about 2616 stock, go to TipRanks’ Stock Analysis page.